This 'telephone' has too many shortcomings to be seriously considered as am eans of communication. The device is inherently of no value to us." This was an internal memo written by WesternU nion in 1876. That'sr ight. Without efficient knowledge sharing and technology transfer,e ven the best scientific development may prove to be ad amp squib for along time. The Basel Life Science Week was created in order to promote scientific and economic exchange and pave the way for innovative ideas. That'swhy NTN Swiss Biotech has moved its traditional 'Olten Meeting' to the Basel Life Science Week. It is the ideal setting for NTN Swiss Biotech and the School of Life Sciences FHNW to present innovative developments within its network of academic and industrial partners in the futureoriented disciplines of Molecular Diagnostics and Medicinal Chemistry.S hort summaries of the key lectures arer eported below.
Part 1: Molecular Diagnostics How To Detect Viral and Bacterial Infections and Genetic Disorders
Molecular diagnostics is particularly on trend as this technology 'sniffs out' specific -p otentially disease-relatedsequences in DNAorRNA.Clinical applications are numerous, ranging from infectious diseases and pharmacogenomics to oncology,genetic disease screening, human leukocytes, antigen typing and coagulation. During the Basel Life Science Week, from 19-23 September 2016, international speakers presented their topics under the motto 'Molecular Diagnostics brought by NTN Swiss Biotech'. The forum waschaired by Eric Kuebler and Daniel Gygax from the School of Life Sciences FHNW.
Pioneer Performance in Gene Expression Assays
Howcan we monitor hundreds of thousands of genes at once in ah igh-throughput system? Harper Va nSteenhouse,d irector of BioSpyder Technologies Inc., has developed an ovel, highly multiplexed, targeted RNAe xpression assay called TempO-Seq™, which leverages the efficient use of existing NGS (nextgeneration sequencing) instruments for readout. Its unique attributes mean that it can be used in manyh igh-throughput applications where RNA-Sequencing or other methods are too limited in performance or throughput or are cost-prohibitive. TempO-Seq™ achievese xceptionally high performance by utilizing annealing and ligation steps without the limitations of reverse transcription or preamplification. The assay generates a reduced-complexity barcoded and pooled NGS library,isrobust to sequencing errors and minimizes necessary bioinformatics. It supports very high throughputs with 384+ samples multiplexed per flowcell lane.
"The capture-free assay is simple to perform manually in a 96-well format in less than 8h ours using common laboratory equipment, including anyP CR/qPCR instrument, and can be automated", explained Va nSteenhouse. "Asa ne xample of TempO-Seq™ performance, we describe the highly sensitive and quantitative whole transcriptome and targeted surrogate panel gene expression profiling from 1m m 2 areas of 5 µm formalin-fixed, paraffin-embedded (FFPE) sections of normal and cancerous tissue within the same prostate to identify disease biomarkers and mechanistic pathways. Both panels identified differentiating biomarkers and mechanistic pathways in prostate cancer."
With TempO-Seq ® ,l arge cohorts of data takem inutes to analyze, and pooling samples and multiplexing 1000s of genes makes sequencing extremely cost-effective,w ith up to 6,144 samples in one sequencing run. We gain deeper insights, as it is possible to analyze anyn umber of targets while processing hundreds to millions of samples. The method is simple: there are no captures or bead-based cleanup steps, it is modular and scalable and it brings the power of targeted sequencing to highthroughput sample processing with the use of template-dependent oligo ligation.
http://biospyder.com
The Fight against Drug-resistant Tuberculosis
The WHO statistics are frightening: nearly half amillion new cases of drug-resistant tuberculosis (DR-TB) emerge each year and, in certain countries, serious epidemics jeopardize progress. In 2014 alone, an estimated 190,000 people with DR-TB died. Dr. Christopher Gilpin,Senior Scientist, Global TB Programmes at WHO, explained the current situation and howhis organization is fighting against this intractable disease with determination: the diagnosis and treatment of DR-TB are indeed ar eal challenge, butt here are effective treatments available. "Wec all for early diagnosis and initiation of appropriate treatment of all persons of all ages with anyf orm of drug-susceptible or drug-resistant TB", recalled Christopher Gilpin, who has over2 0y ears' experience as am icrobiology scientist managing laboratories in Australia and the Middle East. This requires ensuring access to WHO-recommended rapid diagnostics that can detect TB early on in the disease process, along with universal access to drug susceptibility testing (DST) to detect drug-resistant forms. An umber of laboratory tools are available to diagnose DR-TB, including phenotypic culture-based DST and molecular methods. Molecular methods are ar apid alternative (results available in asingle day) compared to culture-based DST,where results are often only available after several weeks. "Optimal and complementary use of the available diagnostic tools at the different levels of the tiered network of TB laboratories is critical. Accurate and timely diagnosis of DR-TB is essential to enable effective treatment and care of patients", explained Christopher Gilpin, who holds ad octorate in TB diagnostics and molecular epidemiology and am aster of Public Health degree focused on tuberculosis and migration. Tools for sequencing and analyzing the genome for Mycobacterium tuberculosis in order to detect mutations associated with drug resistance have become widely biotechnet Switzerland Hot from the press! accessible. "But greater understanding of the relationship between the mutations detected and patient outcomes is still needed for clinical decision making. Important topics in Medicinal Chemistry are the binding affinity as one of the major criteria in the prediction of potency for noveld rug molecules. Our understanding of kinetic and thermodynamic parameters in drug-binding leads to advances in drug discovery.T he forum provided an insight into new macrocyclic drug discoveries and therapeutic opportunities for peptides in oncology and diseases with unmet medical need. This forum waschaired by Gerhard Grundler and Daniel Gygax from the School of Life Sciences FHNW.
The DiscoveryofL TX-315
Bengt Erik Haug,Professor at the Department of Chemistry at the University of Bergen, is interested in the design and synthesis of biologically active peptides and peptidomimetics as well as the synthesis of marine natural products and analogues. Cationic antimicrobial peptides derivedf rom host defence peptides (HDPs), which play an important role in the first line defence against pathogens for most species, have been targeted as novela ntimicrobials and anticancer agents. "In manyc ases, the antimicrobial and cytotoxic activities come from peptidemembrane interactions implicating anionic constituents on bacterial cell surfaces and membranes in cancer cells", explained Haug. The membranolytic mode of action of cationic anticancer peptides includes the release of danger-associated molecular pattern molecules (DAMPs) and tumour antigens from cancer cells, resulting in regression of solid tumours and systemic tumour specific immune response (Ref) .
"Thus, the concept of oncolytic peptides as anoveltherapeutic modality has emerged as ap romising immunotherapeutic strategy for cancer", said Haug, who worked at Lytix Biopharma for four years. "In our efforts to develop oncolytic peptides, initially through modification of the HDP bovine lactoferricin, we identified as eries of chemically modified 9-mer cationic peptides with high cytotoxic activity against both drug-resistant and drug-sensitive cancer cells and lower toxicity towards normal cells."
Among these peptides, LTX-315 displayed superior anticancer activity and wass elected as al ead candidate by Lytix Biopharma AS. Preclinical studies showed that LTX-315 has relatively high plasma protein binding abilities and ah uman plasma half-life in vitro of 160 min. In addition, LTX-315 demonstrated relatively lowa bility to inhibit CYP450 enzymes and wasm etabolized into non-toxic metabolites. And Haug concluded: "LTX-315 is nowi nc linical development as an ew anticancer agent for intra-tumoral administration by Lytix Biopharma, and is currently being evaluated in aphase Istudy." http: //www.uib.no /Bengt-Erik.Haug@uib.no Macrocycles -Panacea for unmet Medical Needs?
The Swiss companyP olyphor Ltd. is focusing on the discovery and development of macrocycle drugs for highly unmet medical needs. These macrocycles represent an ew drug class that complements the classical small molecules and large Diagnosis and treatment of drug-resistant tuberculosis areindeed areal challenge, but effective treatment is available. Source: WHO Preclinical studies show that LTX-315 has relatively high plasma protein binding abilities and ahuman plasma half-life in vitro of 160 min. Lytix Biopharma AS selected LT-315 as alead candidate as it displays superior anti-cancer activity.Source: Lytix Biopharma AS POL6014 is anovel, highly potent, selective and reversible inhibitor of human neutrophil elastase (hNE), akey target for the treatment of respiratory diseases like chronic obstructive pulmonary disease (COPD), cystic fibrosis (CF) and alpha-1-antitrypsin deficiency (AATD). Source: Polyphor Ltd.
The interest of the audience in both events at the Basel Life Science Week shows the need for closer links between academia and industry.S imply publishing research results in important journals provides no guarantee that the newf indings will help us develop newprocedures and products. First of all we have to develop newtechnologies. Researchers achieve this only through effective cooperation with innovative industrial partners. NTN Swiss Biotech pavesthe wayand leads to success! Yo ur contact partner for inquiries: Profesor Dr.Daniel Gygax FHNW Muttenz E-mail: daniel.gygax@fhnw.ch Received: November 3, 2016 biopharmaceuticals.Within this strategy,Polyphor has established twoc omplementary,f ully proprietary macrocycle technologies, PEMfinder ® (macrocyclic peptides) and MacroFinder ® (nonpeptidic macrocycles). As Daniel Obrecht,co-founder and Chief Scientific Officer explained, both technologies yield compounds that are synthetically accessible, amenable to arapid and efficient optimization process. Theyh aveap rovenp otential to provide innovative drug candidates for complextarget classes, including large surface protein-protein interactions.
The investigations carried out showinnovative newfindings: POL6014 is ahighly potent and selective macrocyclic inhibitor of human neutrophil elastase (HNE) and is administered by aerosol inhalation. "POL6014 is currently in Phase Iclinical development with the focus on cystic fibrosis (CF), non-cystic fibrosis bronchiectasis (NCFB) and other rare lung diseases", explained Daniel Obrecht, who spent manyy ears at the Central Research Laboratories of Roche in Basel. "Our macrocycle pipeline also includes novelb reakthrough antibiotics for the highlyselective treatment of serious infections caused by Pseudomonas aeruginosa, as well as ap reclinical programme targeting multidrug-resistant Gram-negative ESKAPE pathogens."
The transition from bench to bedside is within reach: preclinical pharmacological studies reveal that POL6014 inhibits the aggressive,t issue-degrading enzyme neutrophil elastase in ah ighly potent, selective and reversible manner.A fter local application to the lungs by inhalation, POL6014 reaches high concentrations in the lung while the systemic exposure remains low, thus reducing the risk of side effects. Toxicology studies show that POL6014 is very well tolerated by aerosol administration. POL6014 is in Phase Iclinical development.
www.polyphor.com / daniel.obrecht@polyphor.com
